Updated:
Genenta Science S.p.A.
Genenta Science S.p.A. is a publicly traded Milan-based biotech developing cell-based immunotherapy targeting solid tumors.
Genenta Science S.p.A.
Genenta Science S.p.A. is a biotechnology company founded in Milan, Italy, and listed on the AIM Italia market since 2020. The firm focuses on developing a therapeutic platform that uses a patient's own hematopoietic stem cells, modified with genetic material, to direct an immune response against solid tumors. Its lead candidate, Temferon, is in early-stage clinical trials for glioblastoma multiforme. The company's technology platform targets the tumor microenvironment by delivering interferon-alpha directly to tumor-infiltrating macrophages and monocytes. Clinic sites include the San Raffaele Hospital in Milan and additional centers in the United States. Genenta's approach is designed to limit systemic toxicity while achieving localized immune activation. The firm has collaborated with academic institutions such as the Dana-Farber Cancer Institute. As of late 2023, Genenta had fewer than 30 employees and maintained its headquarters in Milan, with a subsidiary in New York. The IPO proceeds of 20 million euros are being used to fund clinical trials and platform expansion. The company also benefits from a research collaboration with the Telethon Foundation for gene therapy applications. Genenta is structurally distinct as a publicly traded biotechnology firm, not a family office, asset manager, or investment vehicle. Its business model relies on academic partnerships and capital markets for funding, and its sole product is its immunotherapeutic platform. The firm has not disclosed plans to diversify beyond oncology.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Italy
City
Milan
Corporate office
Milan, Italy
Principals
Pierluigi Paracchi
Chief Executive Officer
Sector focus
Frequently asked questions
What is Genenta Science's primary technology platform?
Genenta Science develops Temferon, a therapeutic platform that genetically modifies a patient's hematopoietic stem cells to deliver interferon-alpha to tumor-infiltrating macrophages and monocytes. The goal is to activate the immune system locally within the tumor microenvironment, minimizing systemic side effects. The approach combines gene therapy with cell-based delivery.
Is Genenta Science a family office or an investment firm?
No. Genenta Science S.p.A. is a publicly traded biotechnology company listed on the AIM Italia market. It raises capital through equity offerings and collaborations, not through fund structures or direct investments. The firm's operations are entirely focused on developing its own therapeutic products.
What clinical stage is Genenta's lead asset in?
Genenta's lead candidate, Temferon, is in early-stage clinical trials — specifically Phase 1/2 — for glioblastoma multiforme (GBM), an aggressive form of brain cancer. Interim data were presented in October 2023 at a medical conference. The company has not yet advanced to later-stage trials.
How does Genenta fund its operations?
Genenta Science has relied on public market financing, including a 20-million-euro IPO in 2020 on the AIM Italia market, and additional capital raises. The company also maintains research collaborations with not-for-profit entities like the Telethon Foundation. It does not disclose any permanent investment capital or endowment.
Who are the scientific co-founders of Genenta?
The company was co-founded by Luigi Naldini, a recognized gene therapy researcher at the San Raffaele Scientific Institute, and by Pierluigi Paracchi, who serves as CEO. Naldini's work in lentiviral vectors underpins the platform. Full founder details are not publicly aggregated but are cited in press releases.
Where are Genenta's clinical trial sites?
Genenta's primary clinical site is at the San Raffaele Hospital in Milan, Italy. The company also has sites in the United States, including centers collaborating with academic partners. The firm's New York subsidiary supports U.S. regulatory and clinical operations.
Does Genenta have any approved products or revenue?
No. As of 2024, Genenta Science has no approved therapies and reports minimal revenue. The company is a pre-commercial biotechnology firm with expenses largely directed to research and clinical development. Investors should expect no near-term product sales.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: